Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in 2026. Learn why MAZE stock is a strong buy.
A Quick Take On Maze Therapeutics, Inc. Maze Therapeutics, Inc. (MAZE) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is a ...
Maze Mobile has their way of celebrating the new year of 2018 through giving their fans a chance to redeem their points from their purchase of any Maze Mobile products starting froom January Ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results